Shopping Cart
Remove All
Your shopping cart is currently empty
SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 5 mg | $61 | In Stock | In Stock | |
| 10 mg | $107 | In Stock | In Stock | |
| 25 mg | $239 | In Stock | In Stock | |
| 50 mg | $397 | In Stock | In Stock | |
| 100 mg | $627 | In Stock | In Stock | |
| 200 mg | $892 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $68 | In Stock | In Stock |
| Description | SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway. |
| In vitro | SJ000291942 is the most potent compound in causing severe ventralization in embryos, displaying higher mortality rates at lower doses compared to controls and two other compounds, indicating its strong induction of ventralization through enhanced BMP signaling activity. It elevates bmp2b and szl expression levels, suggesting activation of the canonical BMP signaling pathway in zebrafish assays. Further, immunoblotting experiments on C33A-2D2 cell lysates treated with SJ000291942 show its ability to activate SMAD1/5/8 phosphorylation within 1 hour in a serum-free medium, mirroring its high activity observed in zebrafish. Additionally, SJ000291942 significantly induces phosphorylation of Extracellular Signal-regulated Kinase, ERK1/2 (P-ERK1/2). High doses of BMP4 treatments (100 and 300ng) result in a gene expression profile similar to that of osteoblasts, while a low dose (10ng) of BMP4 closely matches the effects observed with 25μM of both compound 3 and SJ000291942 treatments. |
| Molecular Weight | 318.3 |
| Formula | C16H15FN2O4 |
| Cas No. | 425613-09-8 |
| Smiles | CCc1ccc(OCC(=O)Nc2ccc(F)c(c2)[N+]([O-])=O)cc1 |
| Relative Density. | 1.327 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (188.5 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.28 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.